Thymopoietin pentapeptide treatment of primary immunodeficiencies.
26 patients with primary immunodeficiencies (3 infants with severe combined immunodeficiency [SCID] 3 with DiGeorge syndrome, 6 with T-cell defect or SCID with B cells, 4 with common variable hypogammaglobulinaemia and associated T-cell defect, 5 with ataxia-telangiectasia, and 5 with hyper-IgE syndrome) were treated with thymopoietin pentapeptide (TP-5) at a dose of 0 . 5 mg/kg daily for 2 weeks and then 3 times a week at 0 . 5 mg/kg for 10 weeks, 3 patients with DiGeorge syndrome and 3 with primary T-cell defect demonstrated pronounced clinical and immunological improvement during treatment. None of the patients with SCID and 3 of 6 patients with SCID with B cells or primary T-cell defect showed any clinical or immunological changes during therapy. In 5 patients with ataxia-telangiectasia clinical manifestations and immunological tests were unchanged by TP-5. Abnormality of T cells in cases of hyper-IgE syndrome was not corrected by TP-5 treatment.
D000293:Adolescent; D000328:Adult; D000361:Agammaglobulinemia / Q000188:drug therapy; D001260:Ataxia Telangiectasia / Q000188:drug therapy; D002648:Child; D002675:Child, Preschool; D004062:DiGeorge Syndrome / Q000188:drug therapy; D005260:Female; D006728:Hormones / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007111:Immunity, Cellular; D007073:Immunoglobulin E / Q000276:immunology; D007153:Immunologic Deficiency Syndromes / Q000188:drug therapy*; D007223:Infant; D008297:Male; D010446:Peptide Fragments / Q000008:administration & dosage / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000276:immunology; D016305:Thymopentin; D013946:Thymopoietins / Q000008:administration & dosage / Q000627:therapeutic use*; D013951:Thymus Hormones / Q000627:therapeutic use*
D006728:Hormones; D010446:Peptide Fragments; D013946:Thymopoietins; D013951:Thymus Hormones; D007073:Immunoglobulin E; D016305:Thymopentin